Harrow, Inc.
HROW Healthcare Drug Manufacturers Specialty & Generic
Harrow, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $272.3 million, up 36.4% from fiscal 2024. In the quarter to June 2026, revenue grew 10.9%, EPS fell 428.6%, free cash flow fell 838.8% and total debt rose 659.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow HROW
Harrow, Inc. (HROW) EV/Sales
As of 16 October 2026, Harrow, Inc. (HROW) trades at a EV/Sales of 4.5×. Over the past ten years it has ranged from 1.4× (February 2017) to 40.0× (March 2015); the current reading is higher than 61% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.3× | 5.53% |
| FY2024 | 6.9× | 80.16% |
| FY2023 | 3.8× | (17.96%) |
| FY2022 | 4.7× | 31.65% |
| FY2021 | 3.5× | 7.13% |
| FY2020 | 3.3× | (7.04%) |
| FY2019 | 3.5× | 35.34% |
| FY2018 | 2.6× | 55.43% |
| FY2017 | 1.7× | 6.18% |
| FY2016 | 1.6× | (78.52%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 6.5× | 15.81% |
| Mar 2026 | 5.6× | (22.32%) |
| Dec 2025 | 7.3× | (7.55%) |
| Sep 2025 | 7.8× | 60.52% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PAHC Phibro Animal Health Corporation compare | 1.5× |
| ANIP ANI Pharmaceuticals, Inc. compare | 1.8× |
| AMPH Amphastar Pharmaceuticals, Inc. compare | 2.0× |
| COLL Collegium Pharmaceutical, Inc. compare | 2.1× |
| CRON Cronos Group Inc. compare | 2.3× |
| PCRX Pacira BioSciences, Inc. compare | 2.3× |
| HROW Harrow, Inc. | 4.5× |
| XERS Xeris Biopharma Holdings, Inc. compare | 5.7× |
| ETON Eton Pharmaceuticals, Inc. compare | 13.2× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)